Browse treatments

…s HCC aetiology influence responsiveness or prognosis following immunotherapy?…

… associated with poor clinical response to standard therapy and immunotherapy. However, its heterogeneity blunts their understanding and func…

… testing with transcriptomic prediction to guide individualized immunotherapy in HCC.…

…r (SCLC) is a recalcitrant malignancy with limited responses to immunotherapy, largely due to its uniquely immunosuppressive tumor microenvir…

…g a rationale for incorporating epigenetic preconditioning with immunotherapy to improve patient outcomes and pointing towards novel biomarke…

…Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment l…

…s typically arising in the thoracic region, often responding to immunotherapy despite poor prognosis. Although rare, these tumours can also o…

…elin, and CEA emerged as the most frequently targeted antigens. Autologous therapy administered via peripheral intravenous infusion represented th…

… in both early-stage and metastatic settings when combined with chemotherapy. Poly (ADP-ribose) polymerase (PARP) inhibitors, particularly o…

…aseline GZMK expression correlated with an improved response to immunotherapy, and anti-PD-1 treatment modulated the spatial distribution of …

… Clinicians should consider optimal pain control in addition to immunotherapy for SPSD triggered by infection.…

…reatment, and advanced-stage patients exhibit poor responses to immunotherapy. Therefore, the exploration of new therapeutic strategies is of…